A ground breaking development in the battle against cervical cancer could soon benefit millions of women.
The pharmaceuticals giant Merck says it has created a vaccine which is 100 per cent effective against two viruses which cause most cases of the disease.
GlaxoSmithKline is working on a similar product.
Merck is hoping to get a licence to market the drug in the US before the end of the year.
“If it had been available for myself I certainly would have had it to stop me going through what I’ve had to go through. I have two daughters and if there is a vaccine to stop them having to go through this then I am definitely an advocate for that.”
Cervical cancer kills around 15,000 women each year in Europe. It is the second most lethal form of the disease after breast cancer in women aged between 15 and 44.
Experts have said that it is still not clear for how long the vaccines could offer protection.